ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
19 Ottobre 2023 - 10:01PM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third
quarter 2023 operating results. Management will also provide a
brief update on the business.
CONFERENCE CALL INFORMATION
To access the live call by phone, please register here. A
dial-in and unique PIN will be provided to join the call. The call
may also be accessed through the Investors and Media section of the
Company’s website, www.immunogen.com. Following the call, a replay
will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019320151/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Dic 2023 a Dic 2024
